22245-96-1

Basic information

• Product Name: 7-NITRO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE
• Synonyms: 7-NITRO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE;3,4-dihydro-7-nitroisoquinolin-1(2H)-one;3,4-Dihydro-7-nitro-1(2H)-isoquinolinone;7-Nitro-2,3,4-trihydroisoquinolin-1-one;7-Nitro-3,4-dihydroisocarbostyryl;7-Nitro-3,4-dihydroisocarbostyril
• CAS NO: 22245-96-1
• Molecular Formula: C₉H₈N₂O₃
• Molecular Weight: 192.17
• Mol File: 22245-96-1.mol
• Article Data: 23

Chemical Properties

• Melting Point: 225-230℃ (acetone )
• Boiling Point: 487.89°C at 760 mmHg
• Flash Point: 248.867°C
• Appearance: /
• Density: 1.366±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.605
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 7-NITRO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-NITRO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE(22245-96-1)
• EPA Substance Registry System: 7-NITRO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE(22245-96-1)

Safety Data

• Hazardous Substances Data: 22245-96-1(Hazardous Substances Data)

Usage

General Description

7-NITRO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE is a chemical compound that belongs to the class of isoquinolinone derivatives. It is a nitro-substituted isoquinolinone and is used in various research applications. 7-NITRO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE has been studied for its potential pharmacological activities, particularly in the field of neuropharmacology. It has been investigated for its effects on neurotransmitter systems and its potential as a drug candidate for the treatment of various neurological disorders. Additionally, it has also been studied for its potential anticancer properties. However, further research is needed to fully understand the chemical properties and potential applications of 7-NITRO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE in the field of medicine and drug development.

InChI:InChI=1/C9H8N2O3/c12-9-8-5-7(11(13)14)2-1-6(8)3-4-10-9/h1-2,5H,3-4H2,(H,10,12)

Upstream product

• 1196-38-9 3,4-dihydroisoquinolin-1(2H)-one 
• 86288-79-1 2,7-Dinitro-3,4-dihydroisocarbostyryl 
• 91-21-4 1,2,3,4-tetrahydroisoquinoline 
• 6552-60-9 3,4-dihydro-2H-isoquinoline-1-thione 
• 2257-09-2 Phenethyl isothiocyanate 
• 66491-03-0 7-amino-3,4-dihydroisoquinoline-1(2H)-one 
• 6970-83-8 ethyl-N-(2-phenethyl)carbamate 
• 64-04-0 phenethylamine 
• 1943-82-4 phenethyl isocyanate 
• 31349-66-3 methyl 2-((phenethylcarbamoyl)oxy)benzoate 
• 555-21-5 4-Nitrophenylacetonitrile 
• 24954-67-4 2-(p-nitrophenyl)ethylamine 
• 83-33-0 inden-1-one 

Downstream Products

• 62541-66-6 2-(2-Aminoethyl)-5-nitrobenzoic acid 
• 66491-03-0 7-amino-3,4-dihydroisoquinoline-1(2H)-one 
• 709040-12-0 1-(8-amino-1-oxo-1,2,3,4-tetrahydro-isoquinolin-7-yl)-3-(2,6-dichloro-phenyl)-thiourea 
• 62541-63-3 5-Iodo-2-(2-pyrrol-1-ylethyl)benzoic acid 
• 62541-67-7 2-(2-Pyrrol-1-ylethyl)-5-nitro benzoic acid 
• 62541-62-2 2-(2-Aminoethyl)-5-iodobenzoic acid hydrochloride 
• 66491-04-1 7-iodo-3,4-dihydro-1(1H)-isoquinolinone 
• 1196-38-9 3,4-dihydroisoquinolin-1(2H)-one 
• 58021-55-9 9-Amino-5,6-dihydro-s-triazolo<3,4-a>isochinolin 
• 42923-79-5 7-nitro-1,2,3,4-tetrahydroisoquinoline 
• 897374-26-4 7-hydrazino-3,4-dihydro-2H-isoquinolin-1-one 
• 1036388-74-5 C₁₉H₂₀N₂O₅ 
• 891782-60-8 7-bromo-3,4-dihydroisoquinolin-1(2 H)-one 
• 1368661-06-6 7-phenyl-3,4-dihydroisoquinolin-1(2H)-one 

Relevant articles and documents

1,2,4-Triazole-3-Thione Analogues with a 2-Ethylbenzoic Acid at Position 4 as VIM-type Metallo-β-Lactamase Inhibitors

Metallo-β-lactamases (MBLs) are increasingly involved as a major mechanism of resistance to carbapenems in relevant opportunistic Gram-negative pathogens. Unfortunately, clinically efficient MBL inhibitors still represent an unmet medical need. We previou

Cyclic-fused ASK1 inhibitor and application thereof

The invention relates to a cyclic-fused ASK1 inhibitor and application thereof, and particularly to a compound shown in formula (I), a pharmacologically acceptable salt and ester thereof, and a stereisomer thereof. The invention further relates to a preparation method of the compound, a pharmaceutic preparation and a pharmaceutical composition containing the compound. The compound of the inventionis capable of effectively inhibiting phosphorylation of amino acid of ASK1, and inhibiting the activation of the ASK1, thereby can be used for treating and/or preventing ASK1-mediated diseases and related diseases.

Facile synthesis of 5-To 7-membered benzolactam compounds via strongly facilitated electrophilic aromtic substitution reaction

We employed our system to activate aromatic ring-Tethered carbamate compounds with trifluoromethanesulfonic acid to obtain benzolactams with 5-To 7-membered rings, and examined the substrate scope and limitations of this activation method. In 5-membered ring formation, a halogen group on the aromatic ring did not greatly affect the reaction yield, but other electron-donating groups inhibited the cyclization reaction, and various side-reactions occurred. In 7-membered ring formation, eletron-donating groups on aromatic ring promoted the cyclization reaction, but cyclization of electron-deficient aromatic rings did not proceed well. The 6-membered ring formation reaction showed the greatest substrate generality.